×
AleAnna Price to Free Cash Flow Ratio 2022-2024 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
AleAnna price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
View More
AleAnna Price to Free Cash Flow Ratio 2022-2024 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
AleAnna price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$73.4B
Chugai Pharmaceutical (CHGCY)
$72.5B
Takeda Pharmaceutical (TAK)
$42.2B
Merck (MKKGY)
$18.5B
Sandoz Group AG (SDZNY)
$17.9B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$16.1B
Neurocrine Biosciences (NBIX)
$14B
Summit Therapeutics (SMMT)
$13.5B
Shionogi (SGIOY)
$11.9B
Madrigal Pharmaceuticals (MDGL)
$6.8B
Orion OYJ (ORINY)
$6.2B
Ionis Pharmaceuticals (IONS)
$5.5B
Corcept Therapeutics (CORT)
$5.2B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.5B
Recursion Pharmaceuticals (RXRX)
$2.8B
Dyne Therapeutics (DYN)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.3B
Soleno Therapeutics (SLNO)
$2B
Indivior (INDV)
$1.7B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Evotec AG (EVO)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B
Harrow (HROW)
$1.3B
Guardian Pharmacy Services (GRDN)
$1.3B